期刊文献+

5-氟尿嘧啶聚己内酯针状植入剂的研究 被引量:4

Study on Acicular Poly(ε-Caprolactone) Implants Containing 5-Fluorouracil
原文传递
导出
摘要 目的以聚己内酯(PCL)为载体材料、聚乙二醇(PEG)或明胶为添加剂,制备和表征含有5-氟尿嘧啶(5-Fu)的针状植入剂,研究植入剂的体外释放行为。方法采用熔融挤出法制备针状含5-Fu的植入剂,利用XRD和SEM表征植入剂的结晶性和形貌。考察药物含量(12.5%,25%,50%)、添加剂种类(PEG,明胶)、添加剂含量(5%,10%,25%)对药物释放行为的影响。结果植入剂表面光滑,药物在植入剂中分布均匀;植入剂中的5-Fu、PCL和PEG均具有一定程度的结晶性;植入剂中药物含量越大、释放越快;添加PEG或明胶,药物释放加快。结论植入剂制备工艺简单可行,改变载药量、添加剂及其用量可调节植入剂中5-Fu的释放行为,针状植入剂可通过注射器直接注入肿瘤部位,可能在瘤内给药方面有很好的应用前景。 OBJECTIVE To prepare 5-fluorouracil (5-Fu) loaded acicular implants and to investigate the in vitro 5-Fu release behaviors. METHODS The 5-Fu loaded implants were fabricated by hot-melting extrusion method, using PCL as matrix, PEG or gelatin as additive. X-ray diffraction (XRD) and scanning electron microscopy (SEM) were used to character the crystallinity and morphology of implants respectively. The influences of drug loading (12.5%, 25%, 50% ), types of additives ( PEG and gelatin), PEG or gelatin content (5%, 10%, 25%)on drug release behaviors were investigated. RESULTS The obtained implants were with smooth surface. 5-Fu was dispersed uniformly in implants. Crystalline of 5-Fu, PCL and PEG in implants were observed. The higher drug loading, the faster drug release. The addition of PEG or gelatin accelerated drug release. CONCLUSION The fabrication process of implants was easy and feasible, drug release behaviors could be adjusted by changing drug loading, types of additives and additive content. Acicular implants could be potential for drug delivery within tumor.
出处 《中国药学杂志》 CAS CSCD 北大核心 2009年第8期602-606,共5页 Chinese Pharmaceutical Journal
关键词 5-氟尿嘧啶 植入剂 聚己内酯 5-fluorouracil implant poly(ε-caprolactone)
  • 相关文献

参考文献10

  • 1JEAN L G. 5-Fluorouracih forty-plus and still ticking. A review of its preclinical and clinical development[J]. Invest New Drugs, 2000, 18 (4) : 299-313.
  • 2ROBERTO L, ROSA O, CESAR T, et al. 5-Fluorouracil plasma levels and biodegradation of subcutaneously injected drug-loaded microspheres prepared by spray-drying poly(D, L-lactide) and poly(D, L-laetide-co-glyeolide) polymers [J]. Int J Pharm, 2007, 338 (1-2) : 180-190.
  • 3LU B. New Techniques and New Dosage Froms of Drugs (药物新剂型与新技术) [M]. Beijing: People's Medicine Publishing House, 1998: 503-515.
  • 4BREM H, EWEND M G, PIANTADOSI S, et al. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phaseltrial[J].J Neurooncol, 1995, 26(2): 111-123.
  • 5SINHA V R, BANSAL K, KAUSHIK R, et al. Poly-ε-caprolaetone microspheres and nanospheres: an overview [J]. Int J Pharm, 2004, 278 (1) : 1-23.
  • 6ROHNER D, HUTMACHER D W, SEE P, et aL Individually CAD-CAM technique designed, bioresorbable 3-dimensional polycaprolactone framework for experimental reconstruction of craniofacial defects in the pig[J]. Mund Kiefer Gesichtschir, 2002, 6(3): 162-167.
  • 7SANDRA H, GERHARD W, SILKE M, et al. Mechanisms controlling protein release from lipidic implants: Effects of PEG addition [J]. J Controlled Release, 2007, 118 (2): 161-168.
  • 8MALLADI S V, RAMESH B, BOYA V K N, et al. Encapsulation efficiency and controlled release characteristics of crosslinked polyacrylamide particles[J]. Int J Pharm, 2006, 320 (1-2) : 131-136.
  • 9GUO Q H, GUO S R, WANG Z M. Estimation of 5-fluorouracil-loaded ethylene-vinyl acetate stent coating based on percolation thresholds [J]. Int J Pharm, 2007, 333 (1-2) : 95-102.
  • 10WANG Y W, HSIN-I CHANG, DAVID F WERTHEIM, et al. Characterisation of the macroporosity of polycaprolactone-based biocomposites and release kinetics for drug delivery [J]. Biomaterials, 2007, 28 (31) : 4619-4627.

同被引文献60

  • 1蒋春莲.卷材涂料用聚酯树脂的研制[J].当代化工,2005,34(1):36-38. 被引量:1
  • 2刘华顶,王世亮,武四化,储成顶,俞敏,吴静.缓释氟尿嘧啶植入剂在大肠癌患者的药动学研究[J].中国新药杂志,2005,14(10):1199-1201. 被引量:44
  • 3Lee.精油亮甲 告别灰指(趾)甲[J].中国科学美容,2007(2):72-73. 被引量:11
  • 4贾骏,段嫄嫄,周建学,张少锋.聚己内酯电纺纤维支架培养人牙周膜细胞的体外研究[J].牙体牙髓牙周病学杂志,2007,17(5):243-246. 被引量:6
  • 5Hatefi A,Amsden B.Biodegradable injectable in situ forming drug delivery systems[J].J Controlled Release,2002,80(1-3):9-28.
  • 6Pechenov S,Shenoy B,Yang MX,et al.Injectable controlled release formulations incorporating protein crystals[J].J Controlled Release,2004,96 (1):149-158.
  • 7Ravivarapu HB,Moyer KL,Dunn RL.Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide[J].Int J Pharm,2000,194(2):181-191.
  • 8Luan X,Bodmeier R.Influence of the poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems[J].J Controlled Release,2006,110(2):266-272.
  • 9Graham PD,Brodbeck KJ,McHugh AJ.Phase inversion dynamics of PLGA solutions related to drug delivery[J].J Controlled Release,1999,58(2):233-245.
  • 10Chen S,Singh J.Controlled delivery of testosterone from smart polymer solution based systems:in vitro evaluation[J].Int J Pharm,2005,295 (1-2):183-190.

引证文献4

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部